During the last session, LENZ Therapeutics Inc. (NASDAQ:LENZ)’s traded shares were 0.53 million, with the beta value of the company hitting 0.49. At the end of the trading day, the stock’s price was $22.39, reflecting an intraday gain of 1.40% or $0.31. The 52-week high for the LENZ share is $25.77, that puts it down -15.1 from that peak though still a striking 57.53% gain since the share price plummeted to a 52-week low of $9.51. The company’s market capitalization is $615.72M, and the average intraday trading volume over the past 10 days was 0.18 million shares, and the average trade volume was 171.62K shares over the past three months.
LENZ Therapeutics Inc. (LENZ) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.00. LENZ has a Sell rating from 0 analyst(s) out of 2 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 2 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.47.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
LENZ Therapeutics Inc. (NASDAQ:LENZ) trade information
LENZ Therapeutics Inc. (LENZ) registered a 1.40% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 1.40% in intraday trading to $22.39, hitting a weekly high. The stock’s 5-day price performance is 2.42%, and it has moved by -0.36% in 30 days. Based on these gigs, the overall price performance for the year is 97.12%. The short interest in LENZ Therapeutics Inc. (NASDAQ:LENZ) is 2.1 million shares and it means that shorts have 17.72 day(s) to cover.
The consensus price target of analysts on Wall Street is $34, which implies an increase of 34.15% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $32 and $36 respectively. As a result, LENZ is trading at a discount of -60.79% off the target high and -42.92% off the low.
LENZ Therapeutics Inc. (LENZ) estimates and forecasts
Yet analysts are ramping up their growth forecast for the fiscal year 2024. Revenue is predicted to grow 82.80% this quarter and then jump 82.50% in the quarter after that.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -483.52%. While earnings are projected to return 67.33% in 2024, the next five years will return 25.90% per annum.
LENZ Dividends
LENZ Therapeutics Inc. is due to release its next quarterly earnings on 2024-Aug-14. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance. Investors should also take the other fundamental and operational aspects into account before investing in the stock. The forward dividend ratio for LENZ Therapeutics Inc. is 0.00, with the dividend yield indicating at 0.00 percent, continuing the trend of increasing dividends in recent years.
